About us

Founded in 2018, Angitia is a clinical-stage biotechnology company focused on the discovery and development of breakthrough therapeutics that address the key unmet medical needs in serious musculoskeletal disease. With the team's experience and scientific expertise in novel drug development, Angitia is dedicated to bringing innovative therapies to help patients in need.

Degenerative Disc Disease
Osteogenesis Imperfecta
Bone Metastasis
Muscle Disorders
Focus on
Musculoskeletal Diseases
More information
Angita is a global company with a diverse team.
Our company culture revolves around respect and equality.
We are committed to fostering employee growth and career development.
Angitia Biopharmaceuticals Announces the Appointment of Michael H. Arenberg as Chief Financial Officer
WOODLAND HILLS, California, USA, April 8, 2024 – Angitia Biopharmaceuticals, a global, clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced the appointment of Michael H. Arenberg, J.D., M.B.A., as Chief Financial Officer (CFO), effective April 8th, 2024.
Angitia Biopharmaceuticals Completes US$40M Second Close of Series B Extension Financing
Angitia Biopharmaceuticals, a global clinical-stage biotechnology company announces the completion of an additional US$40M Series B Extension financing in January 2024 led by YueKai Health, a market-oriented VC funded by GZHT Technology Holding and managed by Yuekai Capital. Combined with the US$46M Series B Extension financing completed in October 2023, Angitia has now raised US$86M in the Series B Extension.
Angitia Biopharmaceuticals Announces the First Subject Dosed in a Phase III Registrational Trial of AGA111, a Drug Candidate for Enhancing Spinal Fusion
Guangzhou, China and Woodland Hills, California, USA – December 8th, 2023, Angitia Biopharmaceuticals, a global clinical-stage biotechnology company, announced today that the first subject has been successfully dosed in a Phase III registrational clinical trial of AGA111.
more news...